Meridian Bioscience Inc

Meridian Bioscience — Q2 FY2022 Earnings Presentation

13 slides from Meridian Bioscience's earnings presentation, May 6, 2022

  1. Slide 1: FY2022 Q2 Results

    FY2022 Q2 Results May 6, 2022 Exhibit 99.2

  2. Slide 2: Forward-looking statements

    The Private Securities Litigation Reform Act of 1995 provides a safe harbor from civil litigation for forward-looking statements accompanied by meaningful cautionary statements. Except for historical information, this presentation contains forward-looking statements within the meaning of Section 27A

  3. Slide 3: Non-GAAP Financial Measures

    Certain financial measures presented in this presentation, such as operating expenses, operating income, operating margin, net earnings and net earnings per diluted share, each on an adjusted basis, excluding as applicable the effects of changes in fair value of acquisition consideration and selecte

  4. Slide 4: Q2 FY2022 Business Highlights

    Record quarterly revenues for Company and both business segments Launched Lyo-Ready™ sample specific master mixes for blood Resumed shipment of LeadCare® II assay ahead of schedule Seamless transition of Board Chairman and addition of new CFO Q2 FY2022 Business Highlights Diagnostics Life Science

  5. Slide 5: FY2022 Second Quarter Earnings Summary

    FY2022 Second Quarter Earnings Summary ($000’s except Per Share Amounts) Adjusted (Non-GAAP) FY2022 FY2021 Change Net revenues $111,231 $85,264 +30% Gross margin % 62% 68% -6 pts Operating expenses(1) Ratio $31,760 29% $25,530 30% +24% -1 pts Operating income Margin % $36,717 33% $32,242 38% +14% -5

  6. Slide 6: FY2022 Second Quarter Operating Segment Highlights

    FY2022 Second Quarter Operating Segment Highlights ($000’s) Diagnostics segment (Adjusted Non-GAAP) FY2022 FY2021 Change Net revenues $41,103 $31,949 +29% Operating income (loss) Margin % $1,589 4% ($348) NMF NMF NMF Diagnostics segment net revenues by: Technology: Molecular assays $4,385 $4,395 --%

  7. Slide 7: FY2022 Fiscal Year Guidance

    FY2022 Fiscal Year Guidance Meridian Bioscience Diagnostics Life Science Prior Guidance (2/4/2022) Updated FY2022 Guidance Meridian Bioscience Consolidated net revenues: $330 to $345 Million Adjusted operating margin: 22.5% to 23.5% Adjusted net earnings per share*: $1.30 to $1.40 Diagnostics Net re

  8. Slide 8: Diagnostics R&D Pipeline (as of 3/31/2022)

    Diagnostics R&D Pipeline (as of 3/31/2022) Breath Immunoassay Molecular Blood Chemistry Feasibility Development Clinicals FDA Liver MBT PMA Add’l Claim (1) C. difficile Shiga Toxin Streptococcus pneumoniae / Legionella RI Panel GI Panel COVID-19 EUA(3) PediaStat Analyzer Lead Expected FY22 FDA Submi

  9. Slide 9: Meridian ESG Efforts Encompass Four Key Areas

    Meridian ESG Efforts Encompass Four Key Areas Advancing Diagnostics to Enable Better Patient Healthcare Outcomes Accelerate diagnostic test development with high-quality Life Science reagents that power hundreds of diagnostic assays across 150+ disease states Supply hospitals, outpatient clinics, re

  10. Slide 10: Life Science Molecular Master Mixes

    Life Science Molecular Master Mixes

  11. Slide 11: Disrupting Molecular Diagnostics Development

    Disrupting Molecular Diagnostics Development Meridian’s innovative sample-specific mixes (qPCR & LAMP) FAST TRACK YOUR R&D BLOOD URINE STOOL SALIVA PLANT/FOOD DNA RNA LIQUID LYOPHILIZED AIR-DRIED SPECIMEN? DETECTING? KIT FORMAT? ONLY ADD Primers & Probes INHIBITOR TOLERANT Master Mixes have everythi

  12. Slide 12: Sample-Specific Mix Customer Trends YTD

    Sample-Specific Mix Customer Trends YTD

  13. Slide 13: Contact: [email protected]

    Contact: [email protected]

Meridian Bioscience — Q2 FY2022 Earnings Presentation on 6ix